… With drug combination screenings, we found that the triple combination of the protein kinase
… and reactivated the RAF/MEK2/ERK1/RSK1 pathway, which eventually circumvented MEK …

… as monotherapy and subsequently in combination with MEK inhibitors (MEKi). In … pathway,
combination treatment can delay the development of resistance due to pathway reactivation …

… in incomplete MAPK pathway inhibition or pathway reactivation, again resulting in relative
resistance to the drug. c Combined BRAF/MEK inhibition results in efficient pathway blockade …

… to BRAF inhibitors is often due to reactivation of the MAPK pathway [11–13]. In an attempt …
combined BRAF inhibitors with downstream MEK inhibitors (trametinib) [12–14]. Combination …

… RAS effector RAF, MEK, or ERK show synergistic effects in neuroblastoma cells harboring
RAS-activating mutations, and combination of SHP099 with MEK inhibitor trametinib reduces …

… use of MAPK/ERK pathway inhibitors as monotherapy and in combination for the treatment
of … rapid resistance and reactivation of the downstream MAPK/ERK pathway occurs in BRAF-…

… MAPK pathway using the BRAF–MEK inhibitor combination, … –MEK inhibitor resistance,
reactivation of the MAPK pathway … multiple mechanisms to reactivate the MAPK pathway and that …

… down the MAPK pathway), together with p53 reactivation (PRIMA-1 … resistance and synergizes
with MEK inhibition to induce … evidence that combining MAPK inhibition to p53 reactivation …

… system and suggest it as a tool for Nis-reactivation studies. … with a combination of the BRAF
inhibitor dabrafenib and MEK … Moreover, we demonstrated that the combination of MEK and …

… The recent approval of the BRAF/MEK inhibitor combination by the FDA in a variety of
BRAF-driven malignancies has highlighted the clinical problem of drug resistance and the urgent …